10月，随着传统旺季的到来，医药行业供给增速有所回升，其中，中成药产量与上月基本持平，化学原料药产量环比增长5.08%。

报告从医药行业事件分析、竞争环境、竞争对手、行业数据等几个方面进行了分析评论。

报告从政策环境、市场行情、厂商动态、科技研发、国际资讯、行业数据、分析评论等几个方面对医药行业进行了分析评论。

10月上半月，纳入统计的20类主要疫苗品种总批签发量为764.29万剂，同比大幅减少77.77%。

报告从产业动态、产业分析、技术趋势、企业跟踪、地方动向等几个方面对生物科技产业进行了分析评论。

Cancer occurs when, after undergoing cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is considered to be a major cause of lung cancer, though it also occurs in non-smokers.

Human growth hormone is a proteinaceous hormone consisting of 191 amino acid residues secreted by the anterior part of the pituitary gland. In children and adolescents, it promotes linear growth.

Obesity is a medical condition in which surplus body fat gets accumulated to a degree and can ave a detrimental effect on the health of the individual. People suffering from obesity weigh 20 ercent or more than their ideal body weight.

In previous studies we have demonstrated that the ovarian cancer antigen CA125 specifically binds to certain sunsets of immune cell. Based on these observations we have hypothesized that proteomic and transciptomic analysis of immune cells from ovarian cancer patients will result in the identification of specific biomarkers in the immune cells. The current proposal will further investigate this hypothesis by conducting in-depth proteomic analysis of immune cells from cancer patients and healthy blood donors. Studies conducted have resulted in development of streamlined protocols for proteomic analysis of human immune cells. Proteomic analysis of human NK cells has been completed. In addition to proteomic analysis we have also compared the transcriptome of immune cells from ovarian cancer patients and healthy donors and have identified approximately 1600 genes that are differentially expressed in the patient samples. On-going research is focused on validating the proteomic and transcriptome data and demonstrating changes immune cells in response to cancer antigens.

During Year 4, revisions were made to the protocol which allowed female participants to be dosed within either phase of the menstrual cycle so long as they do not meet criteria for Premenstrual Dysphoric Disorder and/or moderate to severe Premenstrual Syndrome. Likewise, modifications to recruitment materials and compensation schedules have increased enrollment and retention. Safety reports continue to be sent to Actelion on a monthly basis. Both blinded and unblinded monitoring visits of study procedures and facilities are ongoing. Throughout Year 4, many new study team members were hired and trained (Study Coordinator, Recruiter, and Research Assistant). The study team also expanded to include additional informed consent administrators, clinical interviewers, as well as sleep technicians and neuropsychological assessment administrators in order to reach the our quarterly enrollment goals. Enrollment is expected to increase due to the actions taken above.